Vivimed Labs Share Price Today

Vivimed Labs seeks 3-month extension to convene FY26 AGM

Vivimed Labs CoC approved applying for a 3-month AGM extension. Application filed with Registrar of Companies, Bangalore. Resolution passed via circulation on September 25, 2026. Extension sought for FY26 Annual General Meeting.

Vivimed Labs reports widened net loss in FY26 amid CIRP

Vivimed Labs Limited reported a widened consolidated net loss of ₹1,764.72 million for FY26, with revenue from operations falling to ₹699.89 million. Total expenses increased to ₹2,526.43 million. Auditors SVRL & Co. issued a qualified opinion due to unrecorded interest expenses of ₹625.72 million, leading to an understatement of loss. The NCLT admitted a petition and initiated CIRP on April 15, 2026, with the first Committee of Creditors meeting held on May 13, 2026.

Vivimed Labs confirms no encumbrance on promoter shares in FY26

Vivimed Labs filed disclosures with BSE and NSE confirming that its promoters did not create any encumbrance on their shareholdings during the financial year ended March 31, 2026. The declaration was submitted in compliance with Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. Company Secretary Kopparthi Yugandhar submitted the filing on behalf of the company.

Vivimed Labs postpones board meeting for FY26 results

Vivimed Labs Limited has postponed its Board Meeting scheduled for May 30, 2026, for the approval of financial results for the quarter and year ended FY 2025-2026. The company will inform the stock exchanges of the revised date in due course. The trading window for designated persons remains closed until 48 hours after the declaration of the financial results.

Vivimed Labs Schedules Board Meeting on May 28, 2026 to Approve Q4FY26 Financial Results

Vivimed Labs has scheduled a Board of Directors meeting on May 28, 2026, at Hyderabad, as per a notice dated May 16, 2026. The meeting has been convened under Regulation 29 of SEBI (Listing Obligations & Disclosure Requirements), 2015. The Board will consider and approve audited standalone and consolidated financial results for the quarter and year ending March 31, 2026. Any other business items may also be taken up at the meeting.

Vivimed Labs Limited Enters Corporate Insolvency Resolution Process

Vivimed Labs Limited has entered corporate insolvency resolution process as ordered by National Company Law Tribunal, Bengaluru Bench on 15.04.2026. T Narayana Swamy serves as interim resolution professional, with creditors required to submit claims by 01.05.2026. The process is estimated to conclude by 11.10.2026.